- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 71
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
- Interventions
- 68Ga-NNS309, 177Lu-DFC413
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Transcutaneous Valve Therapies
- Interventions
- Transcutaneous Valve Therapy
- Device
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Calciphylaxis
- Interventions
- Not listed
- Lead sponsor
- Hope Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Albany, New York • Cleveland, Ohio
- Conditions
- Gastrointestinal Cancer
- Interventions
- Mitomycin C, Cisplatin, Sodium Thiosulfate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
- Interventions
- Lifileucel
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
- Interventions
- Lymphodepletion, TCR-T cells (MDG1015)
- Drug · Biological
- Lead sponsor
- Medigene AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Oligoastrocytoma
- Interventions
- Carboplatin, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Mannitol, Melphalan, Quality-of-Life Assessment, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- Interventions
- AL58805, AL8326, Eribulin, Fulvestrant
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Aortic Valve Stenosis
- Interventions
- Transcatheter Aortic Valve Replacement
- Procedure
- Lead sponsor
- The Society of Thoracic Surgeons
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2035
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
- Interventions
- IPI-504
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
- Conditions
- Systemic Sclerosis (SSc), Dermatomyositis, Mixed Connective Tissue Disease (MCTD), Calcinosis
- Interventions
- Sodium Thiosulfate (STS)
- Drug
- Lead sponsor
- Robyn T. Domsic, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Olaratumab, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
- Interventions
- Navtemadlin, Radiation Therapy, Surgical Procedure
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 53
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
- Conditions
- Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Interventions
- Cisplatin, Sodium Thiosulfate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
- Interventions
- Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
- Conditions
- Complication of Hemodialysis, Cardiovascular Diseases
- Interventions
- sodium thiosulfate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Contact Dermatitis
- Interventions
- T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
- Biological
- Lead sponsor
- Allerderm
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- neoadjuvant exercise therapy
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Malignant Glioma
- Interventions
- Carboplatin, Cyclophosphamide, Etoposide Phosphate, Quality-of-Life Assessment, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio • Portland, Oregon
- Conditions
- Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Interventions
- Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Calciphylaxis, Calcific Uremic Arteriolopathy
- Interventions
- Sodium thiosulfate, Placebo
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Huntsville, Alabama • Fort Wayne, Indiana • Bethlehem, Pennsylvania
- Conditions
- Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor, Metastatic Testicular Seminoma, Stage II Testicular Cancer AJCC v8, Stage III Testicular Cancer AJCC v8
- Interventions
- Audiometric Test, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Sodium Thiosulfate Anhydrous
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Sarcoma, Soft Tissue Sarcoma
- Interventions
- Avastin, Doxorubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland